Acumen Pharmaceuticals Presents First Comprehensive Clinical And Biomarker Data For Sabirnetug At American Academy Of Neurology 2024 Annual Meeting
Acumen Pharmaceuticals Presents First Comprehensive Clinical And Biomarker Data For Sabirnetug At American Academy Of Neurology 2024 Annual Meeting
Acumen Pharmaceuticals 在美国神经病学会 2024 年年会上公布了 Sabirnetug 的首份综合临床和生物标志物数据
Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changes
Presentation to be featured during AAN Emerging Science Session
Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024
演示和海报包括有关sabirnetug安全概况、目标参与和流体生物标志物变化的更深入的数据见解
演讲将在 AAN 新兴科学会议期间展出
公司有望在2024年上半年启动评估sabirnetug的第二阶段试验
CHARLOTTESVILLE, Va., April 16, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present the comprehensive clinical and biomarker results from its positive Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) in early AD during an Emerging Science Session...
弗吉尼亚州夏洛茨维尔，2024年4月16日（GLOBE NEWSWIRE）——Acumen Pharmicals, Inc...
登录免费看全文
登录/注册